GVAX immunotherapy News
Most Popular GVAX immunotherapy Story
BioSante, Cell Genesys merge in $38M deals
Cell Genesys has put an end to its financial woes through a $38 million merger with BioSante. The two companies will merge in an all-stock deal; BioSante will be the surviving company. Cell Genesys Read more...
Latest Headlines
- October 7, 2011
- June 30, 2009
- December 3, 2008
- October 16, 2008
- August 27, 2008
- April 1, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
